Triazole derivatives as P2Y14 receptor antagonists
US-10683277-B2 · Jun 16, 2020 · US
US11708346B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11708346-B2 |
| Application number | US-202016936951-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 23, 2020 |
| Priority date | Jul 23, 2019 |
| Publication date | Jul 25, 2023 |
| Grant date | Jul 25, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.
Opening claim text (preview).
What is claimed is: 1. A method for treating neuropathic pain in a subject in need thereof, the method comprising: administering to the subject in need thereof a therapeutically effective amount of an antagonist of P2Y14 of formula (III) or a pharmaceutically acceptable salt thereof, wherein ring A is aryl, heteroaryl, or cycloalkyl; R 1 is —CO 2 H, —CO 2 (C 1 -C 8 alkyl), or a bioisostere of carboxylate; each R 3 is independently C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, hydroxy, hydroxyalkyl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, aryloxy, halo, C 1 -C 8 haloalkyl, C 1 -C 8 haloalkoxy, —CN, —NO 2 , —NR 5 R 6 , —C(O)R 4 , —CO 2 R 4 , —C(O)NR 5 R 6 , —NR 5 C(O)R 4 , —(CH 2 ) m aryl, —(CH 2 ) m heteroaryl, or —(CH 2 ) m heterocycloalkyl; R 4 , R 5 , and R 6 are independently H or C 1 -C 8 alkyl; X 1 is selected from the group consisting of —(CH 2 ) o —, —C(O)—, —C(O)NH—, —OC(O)NH—, —OC(O)—, —C(O)O—, —C(S)NH—, and —SO 2 —; X 2 is selected from the group consisting of wherein R 7 is CH 2 , NH, or O; X 3 is a dendron; X 4 is selected from the group consisting of —(CH 2 )o-, —C(O)—, —C(O)NH—, —OC(O)NH—, —OC(O)—, —C(O)O—, —C(S)NH—, —SO 2 —, —NHC(O)—, and X 5 is a reactive sulfur-containing moiety; m, n, and q are independently 0 or an integer from 1-5; o is an integer from 1-5; and p is 0 or an integer from 1-36. 2. The method of claim 1 , wherein in formula (III), the dendron is carboxyethylpolyamido (CEPAM) dendron that is optionally functionalized in at least one position to include the moiety wherein R 8 is CH 2 , NH, or O, and R 9 is —NH 2 or —CO 2 H.
linked by a carbon chain containing aromatic rings · CPC title
1,2,3-Triazoles · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
for peripheral neuropathies · CPC title
with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.